Compare $AIM vs $ALZN | Chartloom

Compare

$AIM vs $ALZN

AIM ImmunoTech Inc · Alzamend Neuro Inc

AIM

AIM ImmunoTech Inc

ALZN

Alzamend Neuro Inc

Compare $AIM vs $ALZN

Comparing AIM ImmunoTech Inc and Alzamend Neuro Inc

AIMAIM ImmunoTech Inc

ALZNAlzamend Neuro Inc

AIMAIM ImmunoTech Inc

Market cap

$5M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-21.5%

YTD performance

-84.4%

52W performance

-92.8%

FCF yield

-292.9%

ALZNAlzamend Neuro Inc

Market cap

$6M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-29.5%

52W performance

-47.0%

FCF yield

-106.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AIM

ALZN

Detailed metrics comparison

AIM

AIM ImmunoTech Inc

ALZN

Alzamend Neuro Inc

Market Cap

AIM$5M

ALZN$6M

Enterprise Value

AIM$-1M

ALZN$-1M

Price

AIM$0.18

ALZN$1.34

P/E Ratio

AIMN/A

ALZNN/A

P/S Ratio

AIM52.52x

ALZN0.00x

EV/Sales

AIM-13.57x

ALZN0.00x

EV/EBITDA

AIM0.00x

ALZN0.00x

P/B Ratio

AIM0.91x

ALZN1.14x

P/FCF Ratio

AIMN/A

ALZNN/A

EV/FCF

AIM0.09x

ALZN0.17x

PEG Ratio

AIMN/A

ALZNN/A

Forward P/E (NTM)

AIMN/A

ALZNN/A

Forward P/S (NTM)

AIMN/A

ALZNN/A

Revenue (TTM)

AIM$95K

ALZN$0

Revenue Growth (YoY)

AIM-21.5%

ALZNN/A

Forward Rev Growth

AIM-32.4%

ALZN0.0%

Gross Margin (TTM)

AIM-23.2%

ALZN0.0%

Operating Margin (TTM)

AIM0.0%

ALZN0.0%

EBITDA Margin (TTM)

AIM-10985.3%

ALZN0.0%

Net Margin (TTM)

AIM-15021.1%

ALZN0.0%

FCF Margin (TTM)

AIM-15385.3%

ALZNN/A

Net Income (TTM)

AIM$-14M

ALZN$-9M

FCF (TTM)

AIM$-15M

ALZN$-7M

EPS (TTM)

AIM-$0.83

ALZN-$2.03

ROE (TTM)

AIM-13803.0%

ALZN-27788.0%

ROA (TTM)

AIM-17514.0%

ALZN-18419.0%

ROIC (TTM)

AIM-7694.0%

ALZN-27788.0%

Cash

AIM$10M

ALZN$8M

Debt

AIM$4M

ALZN$0

Net Cash/Debt

AIM$6M

ALZN$8M

Current Ratio (TTM)

AIM2.11x

ALZN3.01x

Quick Ratio (TTM)

AIM2.01x

ALZN2.77x

Debt/Equity (TTM)

AIM0.47x

ALZN0.00x

Debt/Assets (TTM)

AIM0.0%

ALZN0.0%

Interest Coverage (TTM)

AIMN/A

ALZNN/A

Net Debt/EBITDA (TTM)

AIM0.00x

ALZN0.00x

Beta

AIM1.35

ALZN0.43

52W Performance

AIM-92.8%

ALZN-47.0%

YTD Performance

AIM-84.4%

ALZN-29.5%

% from 52W High

AIM-93.6%

ALZN-50.0%

% from 52W Low

AIM8.4%

ALZN59.5%

Asset Turnover (TTM)

AIM0.01x

ALZN0.00x

FCF Yield (TTM)

AIM-292.9%

ALZN-106.6%

Earnings Yield (TTM)

AIM-286.0%

ALZN-141.7%

Dividend Yield (TTM)

AIMN/A

ALZNN/A

Rule of 40

AIM-15,406.8

ALZN0.0

EV/GP/RG

AIMN/A

ALZNN/A

Ticker research

View AIM research View ALZN research

Metric	AIM AIM ImmunoTech Inc	ALZN Alzamend Neuro Inc
Market & Valuation
Market Cap	$5M	$6M
Enterprise Value	$-1M	$-1M
Price	$0.18	$1.34
P/E Ratio	N/A	N/A
P/S Ratio	52.52x	0.00x
EV/Sales	-13.57x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.91x	1.14x
P/FCF Ratio	N/A	N/A
EV/FCF	0.09x	0.17x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$95K	$0
Revenue Growth (YoY)	-21.5%	N/A
Forward Rev Growth	-32.4%	0.0%
Profitability
Gross Margin (TTM)	-23.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-10985.3%	0.0%
Net Margin (TTM)	-15021.1%	0.0%
FCF Margin (TTM)	-15385.3%	N/A
Net Income (TTM)	$-14M	$-9M
FCF (TTM)	$-15M	$-7M
EPS (TTM)	-$0.83	-$2.03
ROE (TTM)	-13803.0%	-27788.0%
ROA (TTM)	-17514.0%	-18419.0%
ROIC (TTM)	-7694.0%	-27788.0%
Financial Health
Cash	$10M	$8M
Debt	$4M	$0
Net Cash/Debt	$6M	$8M
Current Ratio (TTM)	2.11x	3.01x
Quick Ratio (TTM)	2.01x	2.77x
Debt/Equity (TTM)	0.47x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.35	0.43
52W Performance	-92.8%	-47.0%
YTD Performance	-84.4%	-29.5%
% from 52W High	-93.6%	-50.0%
% from 52W Low	8.4%	59.5%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-292.9%	-106.6%
Earnings Yield (TTM)	-286.0%	-141.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-15,406.8	0.0
EV/GP/RG	N/A	N/A
Ticker research	View AIM research	View ALZN research

Valuation

P/S Ratio

ALZN

0.00x

AIM

52.52x

EV/FCF

AIM

0.09x

ALZN

0.17x

Growth & revenue

Revenue Growth TTM

AIM

-21.5%

Forward Revenue Growth

ALZN

0.0%

AIM

-32.4%

Profitability & performance

Gross Margin

ALZN

0.0%

AIM

-23.2%

ROE

AIM

-13803.0%

ALZN

-27788.0%

FCF Yield %

ALZN

-106.6%

AIM

-292.9%

52-Week Performance

ALZN

-47.0%

AIM

-92.8%

Detailed metrics comparison

AIM

AIM ImmunoTech Inc

ALZN

Alzamend Neuro Inc

Market Cap

AIM$5M

ALZN$6M

Enterprise Value

AIM$-1M

ALZN$-1M

Price

AIM$0.18

ALZN$1.34

P/E Ratio

AIMN/A

ALZNN/A

P/S Ratio

AIM52.52x

ALZN0.00x

EV/Sales

AIM-13.57x

ALZN0.00x

EV/EBITDA

AIM0.00x

ALZN0.00x

P/B Ratio

AIM0.91x

ALZN1.14x

P/FCF Ratio

AIMN/A

ALZNN/A

EV/FCF

AIM0.09x

ALZN0.17x

PEG Ratio

AIMN/A

ALZNN/A

Forward P/E (NTM)

AIMN/A

ALZNN/A

Forward P/S (NTM)

AIMN/A

ALZNN/A

Revenue (TTM)

AIM$95K

ALZN$0

Revenue Growth (YoY)

AIM-21.5%

ALZNN/A

Forward Rev Growth

AIM-32.4%

ALZN0.0%

Gross Margin (TTM)

AIM-23.2%

ALZN0.0%

Operating Margin (TTM)

AIM0.0%

ALZN0.0%

EBITDA Margin (TTM)

AIM-10985.3%

ALZN0.0%

Net Margin (TTM)

AIM-15021.1%

ALZN0.0%

FCF Margin (TTM)

AIM-15385.3%

ALZNN/A

Net Income (TTM)

AIM$-14M

ALZN$-9M

FCF (TTM)

AIM$-15M

ALZN$-7M

EPS (TTM)

AIM-$0.83

ALZN-$2.03

ROE (TTM)

AIM-13803.0%

ALZN-27788.0%

ROA (TTM)

AIM-17514.0%

ALZN-18419.0%

ROIC (TTM)

AIM-7694.0%

ALZN-27788.0%

Cash

AIM$10M

ALZN$8M

Debt

AIM$4M

ALZN$0

Net Cash/Debt

AIM$6M

ALZN$8M

Current Ratio (TTM)

AIM2.11x

ALZN3.01x

Quick Ratio (TTM)

AIM2.01x

ALZN2.77x

Debt/Equity (TTM)

AIM0.47x

ALZN0.00x

Debt/Assets (TTM)

AIM0.0%

ALZN0.0%

Interest Coverage (TTM)

AIMN/A

ALZNN/A

Net Debt/EBITDA (TTM)

AIM0.00x

ALZN0.00x

Beta

AIM1.35

ALZN0.43

52W Performance

AIM-92.8%

ALZN-47.0%

YTD Performance

AIM-84.4%

ALZN-29.5%

% from 52W High

AIM-93.6%

ALZN-50.0%

% from 52W Low

AIM8.4%

ALZN59.5%

Asset Turnover (TTM)

AIM0.01x

ALZN0.00x

FCF Yield (TTM)

AIM-292.9%

ALZN-106.6%

Earnings Yield (TTM)

AIM-286.0%

ALZN-141.7%

Dividend Yield (TTM)

AIMN/A

ALZNN/A

Rule of 40

AIM-15,406.8

ALZN0.0

EV/GP/RG

AIMN/A

ALZNN/A

Ticker research

View AIM research View ALZN research

Metric	AIM AIM ImmunoTech Inc	ALZN Alzamend Neuro Inc
Market & Valuation
Market Cap	$5M	$6M
Enterprise Value	$-1M	$-1M
Price	$0.18	$1.34
P/E Ratio	N/A	N/A
P/S Ratio	52.52x	0.00x
EV/Sales	-13.57x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.91x	1.14x
P/FCF Ratio	N/A	N/A
EV/FCF	0.09x	0.17x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$95K	$0
Revenue Growth (YoY)	-21.5%	N/A
Forward Rev Growth	-32.4%	0.0%
Profitability
Gross Margin (TTM)	-23.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-10985.3%	0.0%
Net Margin (TTM)	-15021.1%	0.0%
FCF Margin (TTM)	-15385.3%	N/A
Net Income (TTM)	$-14M	$-9M
FCF (TTM)	$-15M	$-7M
EPS (TTM)	-$0.83	-$2.03
ROE (TTM)	-13803.0%	-27788.0%
ROA (TTM)	-17514.0%	-18419.0%
ROIC (TTM)	-7694.0%	-27788.0%
Financial Health
Cash	$10M	$8M
Debt	$4M	$0
Net Cash/Debt	$6M	$8M
Current Ratio (TTM)	2.11x	3.01x
Quick Ratio (TTM)	2.01x	2.77x
Debt/Equity (TTM)	0.47x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.35	0.43
52W Performance	-92.8%	-47.0%
YTD Performance	-84.4%	-29.5%
% from 52W High	-93.6%	-50.0%
% from 52W Low	8.4%	59.5%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-292.9%	-106.6%
Earnings Yield (TTM)	-286.0%	-141.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-15,406.8	0.0
EV/GP/RG	N/A	N/A
Ticker research	View AIM research	View ALZN research